CO-EXHIBITING MPANIES - Lyonbiopôlelyonbiopole.com/wp/wp-content/uploads/2014/12/Book... · -EXHIBITING CO MPANIES AND PARTNERS. RHÔNE-ALPES, AN INNOVATIVE TERRITORY IN THE HEART

FRENCH PAVILION

BOOTH N° 2507

JUNE 15-18, 2015

PHILADELPHIA (PA)

-EXHIBITING MPANIESCO

AND PARTNERS

RHÔNE-ALPES, AN INNOVATIVE TERRITORY IN THE HEART OF EUROPE

2

21st

2nd

3

4th

400

600

RESEARCH & HIGHER EDUCATION CENTERSwith 20,000 students in life sciences and 3,600 researchers

VACCINE MANUFACTURING SITE IN EUROPE

FRENCH BIO & MED TECH REGION* with 600 SMBs and more than 50 000 jobs

9

WORLD-CLASS R&DINFRASTRUCTURES

UNIVERSITY HOSPITALS2,000 clinical trials/year

PUBLIC AND PRIVATE HEALTHCARE INSTITUTIONS32,000 hospital beds in private and public sectors employing over 36,000 people

100,000

JOBS IN HEALTHCARE

SMBsin health and life sciences sectors

* Medical Devices Study, PIPAME 2011 & MIPRA 2013

RESEARCH CENTERS FROM WORLD LEADER COMPANIES:Sanofi Pasteur, Merial, bioMérieux, BD, Fresenius, MedTronic/Covidien, Bayer Corp…

EUROPEAN REGION IN RESEARCH

TABLE OF CONTENTS

> CO-EXHIBITING COMPANIES ADOCIA …………………………………………………………………………………………………………………………………… 5

Alaxia ……………………………………………………………………………………………………………………………………… 6

Alizé Pharma ………………………………………………………………………………………………………………………… 7

BIOASTER ……………………………………………………………………………………………………………………………… 8

CapEval Pharma …………………………………………………………………………………………………………………… 9

CEA Leti …………………………………………………………………………………………………………………………………10

Cytoo ………………………………………………………………………………………………………………………………………11

Elsalys Biotech ………………………………………………………………………………………………………………………12

ERYtech Pharma ……………………………………………………………………………………………………………………13

Eveon ………………………………………………………………………………………………………………………………………14

Flamel Technologies ………………………………………………………………………………………………………………15

Genoway …………………………………………………………………………………………………………………………………16

ImmunID …………………………………………………………………………………………………………………………………17

Kallistem ………………………………………………………………………………………………………………………………18

MaaT Pharma …………………………………………………………………………………………………………………………19

Newtone Technologies ……………………………………………………………………………………………………………20

Orega Biotech …………………………………………………………………………………………………………………………21

PDC*line Pharma ……………………………………………………………………………………………………………………22

TransCure bioServices……………………………………………………………………………………………………………23

Transgene ………………………………………………………………………………………………………………………………24

> LIFE SCIENCES IN RHÔNE-ALPES Only Lyon, Life Sciences, a driving force for Lyon’s economy ……………………………………………… 27

Lyonbiopole, a World Class healthcare Cluster …………………………………………………………………… 29

Accinov, Biomanufacturing THE OPEN WAY ……………………………………………………………………… 31

CLARA, a Research and Clinical Network in Oncology ………………………………………………………… 33

3

-EXHIBITING MPANIESCO

20 economic players represent

This year in Philadelphia,

the industrial & scientific strengths of

the Rhône-Alpes region, under the banner of

Lyonbiopole

4

ADOCIA is a public biotech company listed on Euronext Paris (ADOC). ADOCIA is focused on developing innovative drug delivery systems for therapeutic molecules. Its proprietary BioChaperone® platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients. The company’s objective is to be a global leader in two main medical areas.

Improving diabetes treatmentsIts flagship products in clinical development (Phase I to Phase III):• BioChaperone® Lispro, an ultra fast-acting insulin for improved prandial glucose control – licensed

to Eli Lilly• HinsBet® U100 & U500, fast-acting formulations of human insulin• BC® Combo, a combination of a rapid- and long-acting insulins in a single product• BioChaperone® PDGF-BB, a ready-to-use spray for treatment of the diabetic foot ulcer

Fighting cancer with targeted treatmentsADOCIA has developed technologies to improve the formulation of monoclonal antibodies. In addition, Adocia develops DriveIn®, a nanotechnology which is intended to selectively deliver active chemotherapeutic agents to cancer cells.

ADOCIAContact : Rémi SOULA

115, avenue Lacassagne - F - 69003 LYONTel : +33 (0)4 72 61 06 10 - Fax : +33 (0)4 72 36 39 67

E-mail : [email protected]

www.adocia.com

5

ALAXIAContact : Philippe BORDEAU

60, Avenue Rockefeller - Bâtiment AdenineF - 69008 LYON

Tel : +33 (0)4 37 53 26 37E-mail : [email protected]

www.alaxia-pharma.eu

A private company with strong skills and several patents owned (5 patents and 2 brands) supported by Stragen Healthcare group. Lyon based, infectious diseases worldwide excellence pole location, strong partnership with recognized EU & US research centers. Alaxia develops therapeutic solutions especially for respiratory diseases based on our own peroxidase platform. We can highlight our ALX-009 program for Cystic Fibrosis, 1st product coming out the pipeline; ALX-009 is both an anti-inflammatory & anti-bacteria treatment designed for Cystic Fibrosis indication.

6

ALIZÉ PHARMAContact : Thierry ABRIBAT

15, Chemin du Saquin - Bât G - F - 69130 ECULLY Tel : +33 (0)4 72 18 94 28Fax : +33 (0)4 78 33 36 29


www.alz-pharma.com

Alizé Pharma is a group of companies specialized in the development of innovative biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. Since its creation in 2007 the group has raised 15.1 M€ from private and institutional investors and has acquired and implemented 3 programs. As of 2015, 2 programs are at the clinical stage and a first industrial partnership has been signed.

Alizé Pharma SAS, is developing AZP-531, a stabilized analog of unacylated ghrelin, a physiological gastrointestinal peptide. This program is in Phase II clinical development for the treatment of Prader-Willi syndrome and in Phase Ib for type 2 diabetes. Alizé Pharma II SAS, is focusing on the development of pegcrisantaspase (ASPAREC® / JZP416), a new pegylated recombinant L-asparaginase for the treatment of acute lymphoblastic leukemia (ALL). It is partnered with Jazz Pharmaceuticals (Nasdaq: JAZZ) and is in Phase II/III clinical development. Alizé Pharma III SAS has acquired exclusive worldwide rights on a family of new peptides with bone anabolic properties, to be developed in osteoporosis and other bone diseases. The I-HBD1 program is at the lead optimization stage.

7

BIOASTERContact : Nathalie GARÇON

Bâtiment Domilyon - 321 avenue Jean Jaurès F - 69007 LYON

Tel : +33 (0)4 69 84 26 00Fax : +33 (0)4 69 84 25 80


www.bioaster.org

BIOASTER is a technology institute that transforms ideas and concepts in the field of microbiology to the patient benefit. It leads programs in four major application fields in health-related microbiology and infectious diseases: vaccines, antimicrobials, diagnostics and microbiota.

BIOASTER implements transdisciplinary R&D projects that brings together academics, small and medium-sized enterprises and industrials around thematic and technology units. BIOASTER, an independent non-profit organization, is one of eight French Technology Research Institutes (IRT) created in 2012 at the initiative of Institut Pasteur and Lyonbiopôle. It was funded by CEA, CNRS, INSERM, Danone Nutricia Research, Mérieux Institute and Sanofi Pasteur, and is supported by 40 SMEs in the Lyon and Paris regions as well as the French government, through the “Investments for the future” program, and by the Grand Lyon, La métropole and the Rhône-Alpes region. Based in Lyon and Paris, the BIOASTER team counts 100 members, including 70 world-class scientists and engineers from 16 countries.

BIOASTER welcomes partnerships with organizations of all sizes.

8

CAPEVAL PHARMAContact : Olivier LOGET

Le Forum 2 - 218, avenue Marie Curie F - 74160 - ARCHAMPS

Tel : +33 (0)6 12 13 29 72 / +33 (0)4 56 44 81 15E-mail : [email protected]

www.capeval-pharma.com

Founded in 2010 by Dr. Olivier Loget, DVM, ERT as a consulting company and transformed in 2012 in a so-called SARL company, CapEval Pharma provides pharmaceutical consultancy services from early pre-clinical to clinical development, specifically in the sectors of Safety, Toxicology, Pharmacology, Ophthalmology, ADME/PK, analytical development, QA, CMC-Regulatory Affairs and Compliance.

CapEval’s team of highly qualified pharmaceutical consultants, fluent in three languages, provides scientific advice and training to identify the best approach to move projects quickly through development and onto the commercial market. With experience working in the Biotech, Pharma and CRO sectors, CapEval is uniquely qualified to offer complete outsourcing management services for critical studies and product development.

CapEval offers particular expertise in the fields of due diligence, assessment of both in-and out-licensing programs and gap analysis for determination of project value.

At CapEval we offer also to perform early non-clinical studies (efficacy, PK/PD, PK and toxicology).

9

CEA-LETIContact : Alexandre THERMET

17, rue des Martyrs - F - 38054 GRENOBLE Cedex 9 Tel : +33 (0)4 38 78 21 37


www.cea.fr

Leti is an institute of CEA, a French research-and-technology organization with activities in energy, IT, healthcare, defense and security. Leti is focused on creating value and innovation through technology transfer to its industrial partners. It specializes in nanotechnologies and their applications, from wireless devices and systems, to biology, healthcare and photonics. CEA-Leti operates 8,000-m² of state-of-the-art clean room space on 200mm and 300mm wafer platforms, employs 1,800 scientists and engineers including 250 Ph.D. students and owns more than 2,800 patent families.

The Microtechnologies for Biology and Healthcare Division focuses on the development of micro-nanotechnologies for applications in the fields of medical imaging, security, in vitro diagnostic, nanomedicine, medical devices and environment monitoring. These activities cover the design, integration and qualification of systems comprising sensors (radiation, biochemical, neural activity, and motion detection), actuators, analog front end electronics, acquisition system, signal processing algorithms, data management and control software.

10

CYTOOContact : Luc SELIG

Minatec - BHT Bât. 52 - 7 parvis Louis NéelF - 38040 GRENOBLE


www.cytoo.com

CYTOO has developed MyoScreen ™, the first human skeletal muscle in vitro model compatible with HCS screening. This model has been validated with atrophy and hypertrophy read-outs. It can be used to screen for hypertrophic compounds (sarcopenia, cachexia, animal health, nutraceutics), to test the myotoxicity of compounds in development (assay validated with 60 drugs). MyoScreen ™ can also be used for metabolic and fibrosis studies.

As part of CYTOO’s engagement into drug discovery, we are further exploring the potential of MyoScreen ™ to develop muscle related disease models and developing the first ever human model of neuromuscular junction. We also have initiated a targeted Drug Discovery effort in DMD open to partnership.

CYTOO is developing physiologically relevant cell-based assays compatible with High Content Screening. Besides MyoScreen ™, the company has a strong expertise in skin related models (micro epidermis, skin firmness).

11

ELSALYS BIOTECHContact : Christine GUILLEN

321, avenue Jean Jaurès - F - 69007 LYONTel : +33 (0)3 88 40 41 87Tel : +33 (0)6 37 69 75 15


www.elsalysbiotech.com

Spin-off of the biopharmaceutical company Transgene, ElsaLys develops therapeutic monoclonal antibodies against innovative targets mainly in the field of oncology and ophtalmology. In vivo proof of concept of antibodies for one target are being demonstrated in murine and rabbit models and human antibodies against a second target is currently evaluated.

ElsaLys Biotech is at the interface between academic research and the pharmaceutical industry. In close collaboration with academic partners, ElsaLys generates comprehensive pre-clinical data needed for further clinical development. The selection of the best drug-candidates is based on strong scientific data and an efficient regulatory approach for clinical development, Translational studies are then conducted to choose the best indication and establish new companion tests.

ElsaLys Biotech is always looking for new opportunities to strengthen its existing portfolio.

12

ERYTECH PHARMAContact : Gil BEYEN

60, avenue Rockefeller - Bâtiment AdénineF - 69008 LYON

Tel : +33 (0)4 78 74 44 38Fax : +33 (0)4 78 75 56 29


www.erytech.com

ERYTECH Pharma develops innovative cancer therapies that work by starving tumors. Its first product reported positive Phase III results of its pivotal study in Acute Lymphoblastic Leukemia (ALL) in Europe and is in four other clinical programs: a Phase IIb study in Acute Myeloid Leukemia (AML), a Phase II study in pancreas cancer and an Expanded Access program in ALL in Europe, and a Phase I/II study in ALL in the USA.ERYTECH proprietary technology is based on encapsulation of therapeutic molecules into red blood cells.

The company has a production unit located in Lyon with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements, one with Orphan Europe (Recordati) and one with TEVA.

13

EVEONContact : Valerie ROUX-JALLET

345, rue LavoisierF - 38330 MONTBONNOT SAINT-MARTIN


www.eveon.eu

Eveon develops innovative medical devices that address the needs of patients, doctors and nurses in curative medicine, by automating treatment preparation, facilitating treatment administration and by connecting patients with medical staff.

ISO 13485 certified, Eveon co-develops tailor-made devices for Biopharmaceutical companies. Currently projects are on-going in Oncology, Cystic Fibrosis, Cell therapy, Rheumatoid Arthritis,…

All our solutions :• Adapt to any primary containers (vials, cartridges, PFS,…)• Are compatible with new biologics and complex products (mAbs, viscous products,…), unstable drugs (dry

formulations)• Offer high accuracy administration• Help to maintain patients at home• Contribute to improve compliance

Eveon operates in France with an office in the United States and has projects in clinical phase.

14

FLAMEL TECHNOLOGIESContact : Jean CHATELLIER

33, Avenue du Docteur Georges LevyParc Club du Moulin à Vent - F - 69200 VÉNISSIEUX

Tel : +33 (0)4 72 78 34 34Fax : +33 (0)4 72 78 34 35


www.flamel.com

FLAMEL Technologies (NASDAQ: FLML; www.flamel.com) is a specialty pharmaceutical company utilizing its core competencies in formulation development and drug delivery to develop safer and more efficacious pharmaceutical products, addressing unmet medical needs and/or reducing overall healthcare costs.

FLAMEL currently has approvals for and markets two previously Unapproved Marketed Drugs in the USA, Bloxiverz™ (neostigmine injection) and Vazculep™ (phenylephrine injection). The Company is also developing several products utilizing Micropump® (oral sustained release microparticles of Sodium Oxybate), LiquiTime® (for the extended-release of liquid medicines such as Ibuprofen and Guaifenesin), Trigger Lock™ (for abuse-resistant long-acting opioids) and Medusa™ (a long-acting hydrogel depot used for Exenatide).

FLAMEL’s products are targeting high-value molecules and will utilize either the 505(b)(2) approval process for NDAs or biosimilar pathways ultimately approved by FDA and other regulatory authorities. The Company is headquartered in Lyon, France and has operations in St. Louis, Missouri, USA, and Dublin, Ireland.

15

GENOWAYContact : Kader THIAM

Contact : Stéphane Martinez 181, avenue jean jaurès - F - 69007 LYON

Tel : +33 (0)4 37 65 41 00Fax : +33 (0)4 37 65 41 01


www.genoway.com

genOway designs and develops accurate in vivo preclinical models for target validation, compound efficacy assessment and safety studies. The company holds exclusive intellectual property on key technologies for model creation and provides access to more than 9,500 models of target validation.

14 of the Top 20 Pharmas use our services and benefit from our strong scientific input in preclinical model conception, development, and management of complex projects. Combining our unrivaled scientific expertise with a robust production platform, the focus of genOway is to provide pharmaceutical companies highly relevant and physiological models within the shortest timelines, to speed up preclinical research projects and enhance clinical trial success rates.

Models are provided with all the required Fredom to Operate.

16

IMMUNIDContact : Bernhard SIXT

BHT 52 - 7, parvis Louis Néel - CS 20050F - 38040 GRENOBLE Cedex 09

Tel : +33 (0)4 38 78 57 70Fax : +33 (0)4 38 78 58 37


www.immunid.com

ImmunID has been a pioneer in the immune molecular diagnostic field since 2005. Its two clinical products ImmunTraCkeR® and ImmunIG® evaluate patient immune competence based on T and B cell repertoire diversity, respectively. The company is establishing ImmunTraCkeR® as the general immune companion diagnostic for all immunotherapies and setting the general immune molecular diagnostics standard globally.

ImmunID collaborates with leading clinical research centers and biopharmaceutical companies worldwide to further validate ImmunTraCkeR® as an immune companion diagnostic test for new immunotherapies and to widen clinical utility of its products.

The company is ISO 9001 certified and runs an ISO 13485 accredited production and R&D facility in the MINATEC high-tech campus in Grenoble, France. In addition, ImmunID has applied for CAP accreditation / CLIA certification of its central lab to be able to provide ImmunTraCkeR® routinely to clinical patients in the United States.

17

KALLISTEMContact : Isabelle CANES-CUOC

ENS – 46 allée d’Italie - F - 69007 LYONTel : +33 (0)4 26 23 38 37


www.kallistem.com

Kallistem is a biotech company which develops therapeutic solution for anticipation and treatment of male infertility with cell therapy.

Today, it is widely accepted that in developed countries the number of human spermatozoa per ejaculate has halved during the last 50 years. Male infertility is involved in about 30 % of couple’s infertility. In addition, there is no solution for young boys who have a high risk of sterility after undergoing cancer treatment or treatment for cryptorchidism.

Kallistem aims to help those patients to produce their own spermatozoa, ex vivo.

Kallistem performs also predictive toxicology studies for spermatogenesis concerns.

18

MAAT PHARMAContact : Hervé AFFAGARD

5, place Charles Béraudier - F - 69003 LYON Tel : +33 (0)6 12 64 26 73


www.maatpharma.com

MaaT Pharma (Microbiota as a Therapy) is a preclinical stage biotechnology company aiming to develop innovative treatments to handle unmet medical needs of dysbiosis-related diseases.

MaaT Pharma’s primary goal is to develop safe and standardized microbiotherapy solutions which are intended to restore the gut barrier function of frail patients receiving antibiotics and, therefore, eradicate hospital-acquired pathogens.

MaaT Pharma was co-founded in 2014 by a highly recognized team of scientific experts and entrepreneurs and is also relying on an amazing team of biomanufacturing and clinical development experts. The company will move to a clinical stage before the end of 2015 and establish partnerships with pharmaceutical companies to secure the development of the next steps.

The company raised its first €1 million funds from Seventure (specialized in the Human Microbiome) and co-develops its lead product with the INRA’s laboratories (French National Institute for Agricultural Research, www.inra.fr), a worldwide leader in the microbiome science field and therapeutic applications.

19

NEWTONE TECHNOLOGIESContact : Jean-Michel DELAVAL

13, Bis Place Jules Ferry - F - 69006 LYONTel : +33 (0)4 72 69 83 20


www.newtone.fr

Newtone Technologies is an Image Analysis Research & Development company, developing specific Sensors (VIS/UV/IR), Software and Services for Majors in Health, Dermatology and Cosmetic Industry.

Throughout the creation process of a product, it is subjected to clinical trials to check its tolerance and assess and certify its effectiveness.Newtone offers expertise on the different clinical phases, both in-vivo and in-vitro, by developing expert image capture, highly innovative materials and by producing image analysis for clinical trials in:

• Dermatology (acne, atopic dermatitis, Hyperspectral imaging, wounds…)• Biology (in vivo and in vitro cell trials, cell culture…)• Cancer research• Virology• Toxicology• Medical imaging• Marketing authorizations for drugs (intervention in phases 2 and 3)• Cosmetics (hydration, anti-ageing, anti-wrinkle, pores, spots…)

We are dynamic and passionate and above all, love to rise to all the challenges which arise with every new issue relating to Appearance and Image Analysis.

20

OREGA BIOTECHContact : Jérémy BASTID

Espace Européen - bât G - 15, Chemin du SaquinF - 69130 ECULLY


www.orega-biotech.com

OREGA Biotech is a French venture based in Lyon, which specializes in the development of first-in-class monoclonal antibodies for the treatment of some cancers. Gilles Alberici with more than 25-year experience in the pharmaceutical industry and biotech start-ups, chairs the company. The R&D programs are performed in the laboratories of the cofounders (Drs Bonnefoy, Bensussan and Eliaou) located in Paris and Montpellier as well as within our network of academic collaborators and industrial partners. Jeremy Bastid, COO, is in charge of the supervision of the work performed by the laboratories and partners worldwide. The current pipeline focuses on the tumor microenvironment. It encompasses monoclonal antibodies targeting a novel immune checkpoint (CD39, immunotherapy) and cancer-related inflammation (IL-17). OREGA Biotech’s business strategy is to bring in parallel several R&D programs into advanced preclinical or early clinical stages, and then to license them out to larger pharmaceutical companies. OREGA Biotech is also keen to enter into early-stage agreements with Pharma/Biotech companies.

21

PDC LINE PHARMAContact : Laurent LEVY

Petite Halle - 31, rue Gustave EiffelF - 38000 GRENOBLE


www.pdc-line-pharma.com

PDC*line Pharma is a clinical-stage start-up that develops therapeutic cancer vaccines based on the only cell line of Dendritic Cells for therapeutic use to provide a non-toxic and long-lasting control of cancer.

The only therapeutic cancer vaccine marketed in USA is based on dendritic cells (for prostate cancer since 2010). However it is an autologous cell therapy and faces industrial challenges. Our technology, based on a Plasmacytoid Dendritic Cell line (PDC*line) is highly scalable, even more potent than conventional dendritic cell-based vaccines, very versatile to any cancer type (changing the tumor peptides), and greatly synergistic with anti-PD-1 checkpoint inhibitors.

Our first candidate is tested in phase 1 on melanoma patients, and our next candidate is in preclinical development for lung cancer. PDC*line Pharma is raising capital for clinical PoC trials in both indications.

Spin-off of the French blood bank (EFS) in 2014, PDC*line Pharma won 4 awards including the Grand Prize for life sciences of the French start-up competition «Tremplin Entreprises».

22

TRANSCURE BIOSERVICES Contact : Yannick ROMERO

260, Avenue Marie Curie - F - 74160 ARCHAMPS Tel : +33 (0)4 56 44 81 21


www.tcbioservices.com

TransCure offers pre-clinical contract research services to pharmaceutical, biotech, start-up and academic researchers who need faster, smarter and cost-effective solutions for drug profiling. Uniquely designed animal models with functional humanized systems have been developed to provide predictive in vivo pharmacology testing in the field of inflammation, & autoimmune (IBD, RA, SLE, MS), anti-infective (HIV, EBV, CMV, Dengue), vaccine development, biosimilar and preclinical lead candidate selection/validation for drug development.

Our customer-oriented approach includes co-designing of experiments with customers to match their needs, diligently and carefully performing the ordered studies and providing comprehensive data analysis and reporting. We are also committed to the 3R principles “reduce, refine and replace” and carefully design the experiments to refine and reduce the use of experimental animals. Located in France, near Geneva, our state-of-the-art animal facilities (BSL 2& 3) and scientific programs are ready to serve customers around the world for their faster access to market entrance.

23

TRANSGENEContact : Simone PERINEL

400, Boulevard Gonthier d’AndernachF - 67400 ILLKIRCH-GRAFFENSTADEN

Tel : +33 (0)3 88 27 91 22Fax : +33 (0)3 88 27 91 11


www.transgene.fr

Immunotherapies for cancer and infectious diseases

Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of cancer and infectious diseases.

24

25

NOTE………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

IN RHÔNE-ALPES

LIFE SCIENCES

26

27

LIFE SCIENCES, A DRIVING FORCE FOR LYON’S ECONOMY

Lyon metropolitan area is today one of Europe‘s most dynamic and attractive place in the field of Life Sciences & Health. Grand Lyon la métropole has a range of responsibilities, including supporting the urban area‘s economic development with a strong emphasis on Life Sciences & Health. Grand Lyon la métropole is a land of innovation & experimentation actively encouraging technological, organizational and social innovation in business. Lyon has a proven track record as a European city of innovation. A local Life Science Network has been created in 2003 under the initiative of the Grand Lyon la métropole who acts as its coordinator. It gathers all organizations active in the Life Sciences’ field, all the skills required to support the development of Life Sciences and increase the attractiveness of the region. The objective of this network is to encourage the setting up, anchoring and development of the Life Sciences & Health businesses in Lyon area. Grand Lyon la métropole also works in close collaboration with all other national and regional authorities. Among our daily partners: Lyonbiopôle, CLARA, Neurodis, CENS, I-Care, Bpifrance, Invest In Lyon, Pulsalys, Université de Lyon, Lyon Chamber of Commerce. Through its partnership-based approach, Grand Lyon la métropole attracts year after year more investors and international business leaders. Grand Lyon la métropole is also investing on developing the Biodistrict Lyon, showcase site of research and bio-industries, to enhance Lyon as one of the main worldwide area hosting biotechnologies and health activities.

STRUCTUREcoordinate and densify the life sciences ecosystem

CONTRIBUTEto the life sciences sector’s outreach through professional events (BIO US/Biovision, etc.)

ENHANCEnetwork by organizing Biotuesday

DEVELOPterritory’s attractiveness with Aderlyand thanks to Biodistrict Lyon

ITS VOCATION 4 excellence fields

Neurology

NutritionOncology

Infectiology

I-CARE, HEALTH TECHNOLOGYRHÔNE-ALPES CLUSTER

C

M

J

CM

MJ

CJ

CMJ

N

Double page Lyonbiopole bis HD.pdf 1 30/04/15 10:25

Clémence LABATLife Sciences DirectorGrand Lyon la métropole20, rue du Lac - BP 3103 - 69399 Lyon Cedex 03Phone: +33(0)4 78 63 42 31 - [email protected] http://www.business.greaterlyon.com/

600

2

60 000

st

FRENCHHEALTH CLUSTER

CLINICAL TESTSPERFORMEDeach year in the Hospices Civils de Lyon

OVER 1000

INDUSTRIALSITESDEDICATED TOLIFE SCIENCES

JOBS IN HEALTH &BIOTECHNOLOGIES

VACCINEPRODUCTIONCENTERin the world Source: Acoss-Urssaf 2013 and Insee-Clap 2012

since 2005 by local companiesin their infrastructures

billion EUROS INVESTED

LIFE SCIENCESCOMPANIESin the region

Spread out over 100 hectares in the south of Gerland,there is a district with an exceptional concentration of key stakeholders: Biodistrict Lyon, the epicenter of life sciencesin Lyon region.

Both a living place and a business district combining industry leaders, SMBs and biotechs, in an advanced scientific and academic environment, Biodistrict Lyon gathers the entire value chain, from science… to life.

C

M

J

CM

MJ

CJ

CMJ

N

Double page Lyonbiopole bis HD.pdf 2 30/04/15 10:25

28

29

A FRENCH HEALTHCARE CLUSTER FOSTERING INNOVATION

> STIMULATE innovation> SUPPORT SMBS’ development> STRENGTHEN the cluster’s international position> DEVELOP a high-level infrastructure offer

154 INNOVATIVE

SMBS

18 RESEARCH &

CLINICAL CENTERS

176 MEMBERS

RHÔNE-ALPES REGION

1ST VACCINE MANUFACTURING

SITE IN EUROPE

4TH EUROPEAN REGION

IN RESEARCH

600 HEALTHCARE COMPANIES

RESEARCHS IN LIFE SCIENCES3,600

-----------------------------------------------------------------

100,000 JOBS INHEALTHCARE 20,000 STUDENTS IN

LIFE SCIENCES-----------------------------------------------------------------

32,000 HOSPITALS BEDS

KEY PERFORMANCE RESULTS

169 COLLABORATIVE R&D PROJECTS SET UP

FOR € 777 M TOTAL INVESTMENT

INCLUDING € 312 M OF PUBLIC FUNDS

70 SMBS SUPPORTED FOR INTERNATIONALIZATION

8 SMBS FUNDRAISING FOR

A TOTAL OF € 71 M IN 2014

19 MEMBERS HOSTED IN3 HIGH-LEVEL INFRASTRUCTURES

DISCOVER LYONBIOPOLE & ITS MEMBER ON WWW.LYONBIOPOLE.COM

4 WORLD CLASS INDUSTRIALS AS FOUNDERS

4 MAIN STRATEGIC AREAS

HUMAN MEDICINE VETERINARY MEDICINE

IN VITRO DIAGNOSTICS MEDICAL DEVICES &MEDICAL TECHNOLOGIES

+ 25% SINCE 2013

LYONBIOPOLE

30

31

For further information, please contact us:[email protected] - www.accinov.com

Benefit from ready-to-use facilities in a unique Lab-Hotel concept

Take advantage of on-site support services

Operate quickly under ISO, GLP, GMP conditions

Rent modularBSL-2 cleanrooms& biomanufacturing units

The innovation platform of Lyonbiopole

Meeting rooms & break rooms

Laboratory support & utilities supplied

Furnished private offices

Industrial state-of-the-art facilities (HVAC, purified water production, process gas...)

Accinov_A4_BAT.indd 1 29/04/14 16:05

32

For further information, please contact us:Accinov, 317 avenue Jean Jaurès - 69007 LYON

+33 4 37 28 73 00 - [email protected] - www.accinov.com

The innovation platform of: With the support from:

Rent private modules

Access shared areas

Benefit from high quality support services

50 sq.m laboratories Biosafety level 2, ISO8 4-6 workplaces

IT roomCold room

Technical support: Monitoring and control of critical parameters, alert management, facilities management and technical maintenance, emergency power supply.

210 sq.m laboratories Biosafety level 2, ISO7 10-12 workplaces

Central cleaning room Liquid nitrogenStorage room

Quality support: Equipment and facilities qualification, quality management system, electronic document management system.

Furnished kitchenMeeting rooms

Administrative support: All-day reception desk (delivery, mail and visitors reception...), site protection (24h/7d alarm and CCTV monitoring).

20 sq.m laboratories Biosafety level 2, ISO8 3 workplaces

More than 1500 sq.m technical areas HVAC, process gas, purified water...

Laboratory support: Media and solution preparation, steam sterilization, waste management.

Purified water, N2, CO2, O2 and compressed air, environmental monitoring (pressure, temperature, freezers and fridges...). All laboratories include furnished offices (12-60sq.m).

L20 L50 P200

Accinov offer: Rent laboratories Access shared areas Benefit from on-site services

ww

w.v

iew

box.

fr

Accinov_A4_BAT.indd 2 29/04/14 16:05

33

YOUR PRIVILEGED PARTNERFOR TRANSLATIONAL RESEARCH ON CANCER

C A N C É R O P Ô L E L Y O N A U V E R G N E R H Ô N E - A L P E S

The Cancéropôle Lyon Auvergne Rhône-Alpes (CLARA) was initiated following the first Cancer Plan and is financed by public authorities.

The objective of the Cancéropôle CLARA is to develop oncology research in Rhône-Alpes and Auvergne by associating academic, clinical and industrial partners from both regions. Our aim is to develop a regional, national and international strategy in the fight against cancer and to encourage technology transfers for the benefit of patients. CLARA’s ambition is to position the Rhône-Alpes Auvergne interregion as an entity of reference in oncology research.

KEY NUMBERS210 academic and clinical teams1 500 cancerology researchers1 700 cancerology health professionals4 university hospital centers2 cancer centers4 universities

Since 2003:€180M financing allocated by local authorities and the National Cancer Institute162 projects supported by CLARA169 scientific events

Seven cancéropôles in France

34

ONCOSTARTER: Accelerate and support project maturation to maximize their chances for future calls for projects

Under the aegis of the Léa & Napoléon Bullukian Foundation

MOBILITY: Support the mobility of young oncology researchers

PROOF OF CONCEPT CLARA : Develop public-private partnerships to accelerate industrial and clinical transfer

SCIENTIFIC ANIMATION: Support cancer research by favoring interregional and interdisciplinary scientific animation and stimulate the development of collaborative projects of excellence

PROJECT EMERGENCE: Initiate and finance the pilot phase of research projects and structuring projects of national visibility

TRANSFER OF ACADEMIC RESEARCH TOWARDS CLINICAL AND INDUSTRIAL APPLICATIONS: Support the transfer of academic research towards clinical and industrial applications through a complete service offer (dedicated financing, training and personalized assistance by experts)

C A N C É R O P Ô L E L Y O N A U V E R G N E R H Ô N E - A L P E S

OUR SUPPORT PROGRAMS

OUR ACTIONS

OUR OBJECTIVESTERRITORIAL VISIBILITY of Rhône-Alpes Auvergne by: better identification of scientific forces, reinforcement of infrastructure services, dynamic clinical research, scientific excellence, international partnerships

ECONOMIC DEVELOPMENT by integrating academic and industrial interests in a model based on four pilars: research organisations, universities, care facilities, enterprises

Cancéropôle Lyon Auvergne Rhône-Alpes321 avenue Jean Jaurès 69007 Lyon

Tel: +33 (0)4 37 90 17 10www.canceropole-clara.com

on www.lyonbiopole.com

FIND YOUR PARTNER IN THE LYONBIOPOLE’S DIRECTORIES

35

on www.lyonbiopole.com

COMPANIES

218INVESTORS

47

RESEARCH UNITS

44 HEALTHCAREINSTITUTIONS

4

R&D PROJECTS

169

Éditi

on 2

015

© L

yonb

iopô

le -

Réa

lisat

ion

: GO

PÉ

Take advantage of our companies’ know-how Contact: Julie-Capucine Hours - Business Development Manager for Americas - [email protected]

www.lyon.cci.fr

Rhône-Alpes, the densest biocluster in EuropeContact: Anne Le Bars - Project Manager - [email protected]

www.espaceentreprises.rhonealpes.fr

Invest In LyonContact: Nathalie Laurent - Life Sciences Manager - [email protected]

www.aderly.com

The bio entrepreneurs’ hubContact: Clémence Labat - Life Sciences Project Director - [email protected]

www.business.greaterlyon.com

INVEST IN LYONGREATER LYON

CCI OF LYON

Diagnostics, Structural Biology and Micronanotechnology Contact: Cyril Isabello - Innovative Project Manager - [email protected]

www.lametro.fr

GRENOBLE-ALPES MÉTROPOLECommunauté d’agglomération

PARTNERS

Documents

CO-EXHIBITING MPANIES - Lyonbiopôlelyonbiopole.com/wp/wp-content/uploads/2014/12/Book... · -EXHIBITING CO MPANIES AND PARTNERS. RHÔNE-ALPES, AN INNOVATIVE TERRITORY IN THE HEART